Inmune Bio Appoints Rare-Disease Execs to Board
Inmune Bio strengthens commercialization and strategy capabilities with the appointment of two executives from Sanofi and biotech leadership roles ahead of Ebstrocel's potential launch.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day